[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529409":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":62,"collaborators":24,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":24,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":24,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-fraction spine SRS","EXPERIMENTAL","Single-fraction spine SRS (22 Gy x 1)",[13],"Radiation: Single-fraction spine SRS",{"label":15,"type":10,"description":16,"interventionNames":17},"Multi-fraction spine SRS","Multi-fraction spine SRS (14 Gy x 2)",[18],"Radiation: Multi-fraction spine SRS",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"RADIATION","Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)",[15],[29],{"name":30,"affiliation":5,"role":31},"Erqi Pollom, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Kelly Huang","CONTACT","650-724-4606","kelhuang@stanford.edu",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Alyssa Yauger","650-498-5271","ayauger@stanford.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Stanford University School of Medicine","RECRUITING","Palo Alto","California","94305","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.14302,37.44188,{"lat":55,"lon":54},[58,59,60],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},{"name":61,"role":31,"phone":24,"phoneExt":24,"email":24},"Erqi L Pollom, M.D.",{"type":63,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100529409","phase-3-comparing-single--vs-multi-fraction-spine-stereotactic-radiosurgery-in-spinal-metastases-100529409",false,"NCT06173401","Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases","A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)","Inclusion Criteria:\n\n* Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer Age ≥ 18 years\n* Patients who have cervical, thoracic, or lumbar spine metastasis that need treatment.\n* Patients will have 1 to 3 separate spinal sites that require treatment.\n* Each spinal site to be treated on trial will span 1-2 contiguous vertebral levels\n* ECOG 0-2\n* Negative serum or urine pregnancy test within 14 days prior to enrollment for people of childbearing potential or who are not postmenopausal\n* people of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control\n* Ability to understand and the willingness to sign (personally or by a legal authorized representative) the written IRB approved informed consent document\n\nExclusion Criteria:\n\n* Prior or planned radiation off study within or overlapping with study treatment site\n* Inability to have either an MRI or a CT scan. Patients with pacemaker will be allowed to undergo CT instead of MRI\n* Pediatric patients (age \\\u003C18 years old), pregnant women, and nursing patients will be excluded\n* Histology's of myeloma or lymphoma\n* Patients with strength 1-3 (of 5), bladder incontinence, bowel incontinence, and\u002For bladder retention that is associated with spinal site to be treated\n* Prior surgery to spinal site intended to be treated with protocol SRS\n* Excluded those with SINS 13-18","ALL","18 Years",{"count":74,"type":75},274,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","The goal of this study is to determine whether fractionated Stereotactic radiosurgery (SRS) for spine metastases is associated with improved local tumor control compared to single-fraction SRS. Patients will be randomized to treatment with spine SRS using either 22 Gy in 1 fraction or 28 Gy in 2 fractions.",[81],"Spinal Metastases",[83,84,85,86,87],"spine stereotactic radiosurgery","cervical","lumbar","thoracic","metastases","2025-07-15",{"date":90,"type":91},"2025-07-16","ACTUAL",{"date":93,"type":91},"2023-12-18",{"date":95,"type":75},"2028-12",{"name":5,"class":6},1]